Umeclidinium bromide

Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).^[3] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol)^[4][5] and also as a triple-therapy combination as fluticasone furoate/umeclidinium bromide/vilanterol.^[6]

Umeclidinium bromide

Clinical data
Trade names	Incruse Ellipta
Other names	GSK573719A
License data	US DailyMed: Umeclidinium bromide
Routes of administration	Inhalation (DPI)
ATC code	R03BB07 (WHO) R03AL03 (WHO) (+vilanterol)
Legal status
Legal status	AU: S4 (Prescription only)[1] CA: ℞-only[2] UK: POM (Prescription only) US: ℞-only In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding	~89%[3]
Metabolism	Liver (CYP2D6)
Elimination half-life	11 hours
Excretion	Feces (58%) and urine (22%)
Identifiers
IUPAC name Diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol bromide
CAS Number	869113-09-7
PubChem CID	11519069
DrugBank	DB09076
ChemSpider	9693857
UNII	7AN603V4JV
KEGG	D10181
ChEBI	CHEBI:79040
CompTox Dashboard (EPA)	DTXSID50235966
ECHA InfoCard	100.166.375
Chemical and physical data
Formula	C29H34BrNO2
Molar mass	508.500 g·mol−1
3D model (JSmol)	Interactive image
SMILES OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2.[Br-]
InChI InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1 Key:PEJHHXHHNGORMP-UHFFFAOYSA-M

It is on the World Health Organization's List of Essential Medicines.^[7] In 2020, it was the 245th most commonly prescribed medication in the United States, with more than 1 million prescriptions.^[8][9]